Press Releases

December 06, 2017
Immunomedics announces updated results with sacituzumab govitecan (IMMU-132) in patients with relapsed or refractory metastatic triple-negative breast cancer (mTNBC)
November 13, 2017
Immunomedics announces presentations and investor event at the 2017 San Antonio breast cancer symposium
November 09, 2017
Immunomedics announces first quarter fiscal 2018 results and provides corporate update
Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth
November 02, 2017
Immunomedics to report first-quarter fiscal 2018 results and host conference call and webcast on November 9, 2017
October 20, 2017
40th Annual San Antonio Breast Cancer Symposium (SABCS 2017)
September 15, 2017
Immunomedics announces agreements to exchange approximately 80M of its 4.75% convertible senior notes dues due 2020 for common stock
September 11, 2017
Immunomedics presents interim phase 2 results with sacituzumab govitecan (IMMU-132) in patients with pretreated metastatic urothelial cancer
August 30, 2017
Immunomedics to participate in upcoming investor conferences
August 21, 2017
Immunomedics announces publication of phase 2 results with labetuzumab govitecan (IMMU-130) that demonstrate promising efficacy as a single agent in patients with metastatic colorectal cancer
August 16, 2017
Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline
August 07, 2017
Immunomedics announces conference call and webcast for fourth quarter and fiscal year 2017 results
July 10, 2017
Published results from clinical trials demonstrate therapeutic potential for Immunomedics’ sacituzumab govitecan (IMMU-132) in the treatment of metastatic solid cancers
June 29, 2017
Immunomedics announces results of special stockholder meeting
June 01, 2017
Immunomedics to present at Jefferies 2017 global healthcare conference
May 10, 2017
Immunomedics announces third quarter fiscal 2017 results and clinical program developments